Overview

Neuroimaging and CBD for Heroin Use Disorder

Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The investigators propose an imaging study to investigate the neurobiological effects of CBD (vs placebo) in abstinent subjects with heroin use disorder (HUD). The purpose of the study is to determine the neural circuits and transmitters associated with the effects of CBD on to reduce craving and anxiety. The neuroimaging will be conducted in participants immediately following their first administration of CBD (800mg or placebo) and one week after the last administration (3 daily doses). This CBD administration protocol was shown in previous studies by the investigators to reduce craving and anxiety in abstinent heroin users.
Phase:
Phase 2
Details
Lead Sponsor:
Hurd,Yasmin, Ph.D.
Collaborator:
GW Research Ltd
Treatments:
Cannabidiol
Epidiolex